UDATING ABOUT SGLT – 2 INHIBITORS IN TREATING DIABETES

Abstract

SGLT – 2 inhibitors are new drugs that have been recently approved by FDA ((U.S. Food & Drug Administration) for treating type 2 diabetes. In clinical trials, these drugs have demonstrated their effects in lowering blood glucose level as well as HbA1c. In addition, they also have reduced weight, systolic blood pressure and blood uric acid. Nevertheless, there have been some common adverse effects of these drugs, like genital mycotic infection, urinary tract infection, osmotic diuresis and volume depletion. Recently, FDA and EMA (European Medicines agency) have showed some warnings associating with common adverse effects of these drugs. SGLT – 2 inhibitors have been proven that they not only can be used in type 2 diabetes, but also have potential in combining with insulin in type 1 diabetes. However, researchers need more time to evaluate exactly about effects and safety of these drugs.